---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-044135"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2023-08-23T23:59:59+00:00"
generated_at: "2026-06-11T04:55:53.420291+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio appoints new CEO, cuts 70% of workforce

## Summary
- Kimberlee C. Drapkin appointed President & CEO, effective Aug 21, 2023; base salary $550,000.
- Board approved a restructuring plan reducing workforce by approximately 70%.
- Estimated severance and related costs of ~$1.6 million, recorded primarily in Q3 2023.
- Former CEO Josh Lehrer separated; entitled to Tier 1 severance and retention benefits.
- Company continues exploring strategic alternatives as part of corporate restructuring.

## SEC filing metadata
- accession: 0000950170-23-044135
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2023-08-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000095017023044135/0000950170-23-044135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000095017023044135/grph-20230818.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-044135
- JSON: https://secwatch.observer/filing/0000950170-23-044135.json
- Plain text: https://secwatch.observer/filing/0000950170-23-044135.txt

## Key facts
- Restructurings & Charges
  LENZ Therapeutics, Inc. announced a restructuring with charges of approximately $1.6 million (approximately 70%).
  - Type: restructuring
  - Charge: approximately $1.6 million
  - Headcount: approximately 70%
  source text: alternatives. Under the Plan, the Company is reducing its workforce by approximately 70%. The Company expects to incur estimated severance and related costs of approximately $1.6 million, which will be recorded primarily in the third quarter of 2023. As the Plan is implemented, the Company’s management will re-evaluate the estimated costs and expenses set forth
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815776/000095017023044135/0000950170-23-044135-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.